Xconomy’s Digital Events →
September 21, 2020 · National
September 24, 2020 · National
November 17, 2020 · New York
Akero’s FGF21 analog yields 63 percent to 72 percent relative hepatic fat reduction in Phase 2a study; the company awaits biopsy data hoping to see a fibrotic benefit. Also, Genfit says... Read more »
Sponsored · Whitepaper
A Guide to Performing Check-ups on Pharmaceutical Distribution & Patient Access Programs
From Our Editors · Special Report
The AI, Big Data, and R&D Boom
Explore the different sources of funding, their relative merits, and how you should best utilize that funding at each stage of your research
© 2007-2020, Xconomy, Inc.
Xconomy is a registered service mark of Xconomy, Inc.
All rights reserved.